Dilemmas in metastatic differentiated thyroid cancer: To irradiate, medicate, or palliate?

Abstract

Aims: To explore the challenges in the management of metastatic differentiated thyroid cancer. Introduction: Differentiated thyroid cancer (DTC) is the most common form of thyroid cancer. The initial diagnosis of thyroid carcinoma and the distinction between benign and neoplastic disease can be challenging. Radioiodine-refractory metastatic DTC also presents a therapeutic dilemma. Novel targeted agents for advanced radioiodine-refractory metastatic thyroid cancer, such as tyrosine kinase inhibitors (TKIs), are being increasingly used with clinical success, broadening current available therapeutic options. Case report: We present the case of a 61-year-old woman with radioiodine-refractory met..